Efficacy of dulaglutide on vascular health indexes in subjects with type 2 diabetes: a randomized trial.

ABSTRACT:

Background

Recent cardiovascular outcome trials have shown significant reductions in major cardiovascular (CV) events with glucagon-like peptide (GLP)-1 receptor agonists. Additionally, adjunctive surrogates for cardiovascular risk validated by some studies include arterial stiffness and endothelial function indexes. To date, no randomized trial has addressed the possible effects of antidiabetic interventional drugs such as GLP1 agonists on endothelial and arterial stiffness indexes as surrogate markers of vascular damage.

Aims

We aimed to evaluate metabolic efficacy and surrogate vascular efficacy endpoints of once-weekly dulaglutide (1.5 mg) plus traditional antidiabetic treatment compared with traditional antidiabetic treatment alone in subjects with type 2 diabetes.

M

SUBMITTER: Tuttolomondo A 

PROVIDER: S-EPMC7784355 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature